Email
Password
Remember meForgot password?
    Log in with Twitter
Press Release

Dec 19, 2018 11:20 UTC

Global Primary Biliary Cirrhosis - API Manufacturers, Marketed and Phase III Drugs Landscape 2018 - ResearchAndMarkets.com

DUBLIN--(Business Wire)--The "Primary Biliary Cirrhosis - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.

The 'Primary Biliary Cirrhosis - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018' report provides comprehensive insights about marketed and Phase III products for Primary Biliary Cirrhosis. The report includes information of marketed products including their product description, patent details, forecasted sales till 2020 & API manufacturer details by country.

Global API Manufacturers of Marketed Products for Primary Biliary Cirrhosis

Coverage of API manufacturers for Primary Biliary Cirrhosis marketed products spanning across United States, Europe, China and India. The manufacturers' details include manufacturers' name along with their location.

Emerging Phase III products for Primary Biliary Cirrhosis

This report provides a comprehensive understanding of the emerging Phase III therapies for Primary Biliary Cirrhosis which can turn out to be future prospective competitors for the marketed products. It will also put light on the current market trends. Their forecasted global sales are also provided till 2020.

Key Topics Covered:

1. Report Introduction

2. Primary Biliary Cirrhosis: Overview

  • Risk Factors
  • Causes
  • Symptoms
  • Pathophysiology
  • Prognosis
  • Diagnosis
  • Treatment

3. Comparative Analysis of Marketed and Emerging Products

4. Marketed Therapies

  • Product Description
  • Route of Synthesis
  • Mechanism of Action
  • Pharmacology
  • Pharmacodynamics
  • Pharmacokinetics
  • Adverse Reactions
  • Clinical Trials
  • Regulatory Milestones
  • Product Development Activities
  • United States
  • Europe
  • Historical Global Sales
  • Forecasted Global Sales

5. Emerging Therapies (Phase III)

  • Product Description
  • Research and Development
  • Product Development Activities

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/4q2p63/global_primary?w=4

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Liver and Kidney Disorders Drugs

Latest News
Top News